Document:

Letter Amendment to the Enzyme and Product Supply Agreement

 Exhibit 10.1 
 

 
 Codexis, Inc. 
 200 Penobscot Drive 
 Redwood City, CA 94063 

Tel: 650.421.8100 

Fax: 650.421.8102 

www.codexis.com 
 April 22,
2011 
 Mr. Ajit Kamath 
 Arch
Pharmalabs Ltd. 
 H Wing, 4th Floor 
 Tex
Centre 
 Off Saki Vihar Road 

Chandivali, Mumbai – 400072 
 India

 RE: Conversion of Exclusivity for Phenylephrine, pursuant to the Enzyme and Product Supply Agreement, effective as of February 16,
2010, between Codexis, Inc. (“Codexis”) and Arch Pharmalabs Limited (“Arch”) (the “EPSA”) 
 Dear
Mr. Kamath: 
 Further to the parties’ discussions regarding the conversion of Arch’s and Codexis’ exclusive relationship to
a Non-Exclusive Relationship with respect to phenylephrine and CDX-004, which is used in the manufacture of phenylephrine and its intermediates (collectively, the “Phenylephrine Products”), in consideration of the continued relationship
between the parties as set forth in the EPSA, Codexis and Arch hereby agree to such conversion on the terms and conditions set forth in this letter. Defined terms used herein but not defined herein have the meanings ascribed to them in the EPSA.

 Notwithstanding anything to the contrary in the EPSA, including without limitation, the non-occurrence of any of the events in
Section 4.1, Arch and Codexis hereby agree that the exclusive relationship set forth in Sections 2.1 and 3.1 shall convert to a Non-Exclusive Relationship. Arch hereby waives any requirements set forth in Section 4.1(a), (b) or
(c) with respect to any condition precedent to converting the Parties relationship with respect to the Phenylephrine Products to a Non-Exclusive Relationship. The terms of this letter agreement shall become effective as of April 22, 2011.

 If you have any questions, please contact Peter Seufer-Wasserthal by telephone (+43 7673 321 511) or email (peter.seufer@codexis.com). For
clarity, nothing in this letter shall be deemed to amend, modify, or supersede the terms agreed to in the EPSA with respect to any Product other than the Phenylephrine Products. 
 Please indicate Arch’s agreement to the above by countersigning each enclosed duplicate of this letter and return one (1) original to the following address: 

Codexis, Inc. 

Attn: Contracts 

200 Penobscot Drive 
 Redwood City, CA 94063 

 

 
  

			
	Best regards,
	
	Codexis, Inc.
		
	By:	 	 /s/    Joseph Sarrett
	Name:	 	Joseph Sarrett
	Title:	 	 CBO & President,

Pharmaceutical Services & Enzyme Products

			
	
	Acknowledged, agreed and accepted by:
	
	Arch Pharmalabs, Ltd.
		
	Signature:	 	/s/    Ajit Kamath
	Print Name:	 	Ajit Kamath
	Date:	 	Chairman & Managing Director

 Bringing Life to ChemistryTMLetter Amendment to the Product Supply Agreement

 Exhibit 10.2 
 

 
 Codexis Laboratories India Private Limited 

G-01, Prestige Loka 

7/1, Brunton Road 

Bangalore, 560 025 

www.codexis.com 
 April 22,
2011 
 Mr. Ajit Kamath 
 Arch
Pharmalabs Ltd. 
 H Wing, 4th Floor 
 Tex
Centre 
 Off Saki Vihar Road 

Chandivali, Mumbai – 400072 
 India

 RE: Conversion of Exclusivity for Phenylephrine, under that certain Product Supply Agreement, effective as of February 16, 2010,
between Codexis Laboratories India Private Limited (“Codexis India”) and Arch Pharmalabs Limited (“Arch”) (such agreement, the “PSA”) 
 Dear Mr. Kamath: 
 Pursuant to that certain letter regarding the conversion of the exclusive
relationship between Arch and Codexis, Inc. (“Codexis”) with respect to phenylephrine to a Non-Exclusive Relationship, effective as of April 22, 2011, between Codexis and Arch (the “Letter”), Arch is permitted to sell
phenylephrine and CDX-004, which is used in the manufacture of phenylephrine and its intermediates (collectively, the “Phenylephrine Products”) to any Third Party. Notwithstanding anything to the contrary in the PSA, in conjunction with
such conversion and subject to the terms and conditions of the Letter, Codexis India hereby consents to allow Arch to sell Phenylephrine Products to Third Parties and Arch hereby consents to allow Codexis India to sell Phenylephrine Products to
Third Parties. The terms of this letter agreement shall become effective as of April 22, 2011. 
 Defined terms used herein but not defined
herein have the meanings ascribed to them in the Letter. If you have any questions, please contact Peter Seufer-Wasserthal by telephone (+43 7673 321 511) or email (peter.seufer@codexis.com). For clarity, nothing in this letter shall be deemed to
amend, modify, or supersede the terms agreed to in the PSA with respect to any Product other than the Phenylephrine Products. 
 Please indicate
Arch’s agreement to the above by countersigning each enclosed duplicate of this letter and return one (1) original to the following address: 
 Codexis, Inc. 
 Attn: Contracts 

200 Penobscot Drive 
 Redwood City, CA 94063 

 

 
  

			
	Best regards,
	
	Codexis Laboratories India Private Limited
		
	By:	 	/s/    Douglas Sheehy
	Name:	 	Douglas Sheehy
	Title:	 	Director

			
	
	Acknowledged, agreed and accepted by:
	
	Arch Pharmalabs, Ltd.
		
	Signature:	 	/s/    Ajit Kamath
	Print Name:	 	Ajit Kamath
	Date:	 	Chairman & Managing Director

 Bringing Life to ChemistryTM<![CDATA[Amd No.1 to the memo of Understanding for Transfer Pricing & Royalty Calculation]]>

 Exhibit 10.3 
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 
 EXECUTION COPY 
 AMENDMENT NO. 1 TO MEMORANDUM OF UNDERSTANDING FOR TRANSFER PRICING AND ROYALTY CALCULATION 
 This amendment (“Amendment No. 1”) is entered into as of April __, 2011 and effective as of January 1, 2011 (the “Amendment Effective Date”) by and between
Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Dr., Redwood City, CA 94063 (“Codexis”) and Arch Pharmalabs Limited, a corporation organized and existing under the laws of India having a place of
business at H wing, 4th Floor, Tex Centre, Chandivali,
Mumbai, 400072, India (“Arch”). 
 WHEREAS, Arch and Codexis are parties to that certain Enzyme and Product
Supply Agreement, effective as of February 16, 2010 (the “EPSA”) and the Memorandum of Understanding for Transfer Pricing and Royalty Calculation related thereto (the “MOU”); and 

WHEREAS, the parties desire to amend the MOU to modify Arch’s manufacturing costs as set forth herein. 

NOW, THEREFORE, in consideration of the premises and mutual covenants contained in this Amendment, the parties agree as follows:

 1. Definitions. The capitalized terms used in this Amendment shall have the meanings assigned to such terms in the
MOU, unless otherwise defined herein. 
 2. Amendment. Arch and Codexis agree that the MOU shall be amended in the manner
set forth below: 
  

	 	A.	The table and the language preceding such table that immediately follows Paragraph F in the definition of “Manufacturing Costs” in Exhibit A of the MOU shall
be replaced in its entirety with the following: 

 Notwithstanding anything to the contrary, combined Direct Labor
Expenses set forth in Paragraph B(ii), Indirect Expenses set forth in Paragraph C, and Overhead Expenses set forth in Paragraph D shall not, in respect of each Product, exceed the following amounts: 

 

			
	 Product
	  	 Current Overhead

[*]

	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 [*] Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXECUTION COPY

  

			
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 The amounts set forth in the above table are subject to quarterly review by the Parties pursuant to
Section 3.3 of the MOU. 
 3. Ratification; Conflict. Except as otherwise expressly set forth in this Amendment, all
of the terms and conditions of the EPSA and MOU shall remain in full force and effect. In the event of any conflict between the terms of this Amendment and the terms of the EPSA and MOU, the terms of this Amendment shall control. 

4. Counterparts. This Amendment may be signed in one (1) or more counterparts, each of which will be deemed an original but
all of which together will constitute one and the same instrument. 
 IN WITNESS WHEREOF, a duly authorized representative of
each party has executed this Amendment as of the dates identified below, but the Amendment shall become effective on the Amendment Effective Date. 
  

									
	CODEXIS, INC.	 		 	ARCH PHARMALABS LIMITED
					
	By:	 	/s/     Joseph Sarrett	 		 	By:	 	/s/    Ajit Kamath
	Name:	 	Joseph Sarrett	 		 	Name:	 	Ajit Kamath
	Title:	 	Chief Business Officer	 		 	Title:	 	Chairman & Managing Director
	Date:	 	April 20, 2011	 		 	Date:	 	April 25, 2011Amendment No.1 to the memorandum of Understanding for Transfer Pricing

 Exhibit 10.4 
 [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted
portions. 
 EXECUTION COPY 
 AMENDMENT NO. 1 TO MEMORANDUM OF UNDERSTANDING FOR TRANSFER PRICING 
 This amendment (“Amendment No. 1”) is entered into as of April __, 2011 and effective as of January 1, 2011 (the “Amendment Effective Date”) by and between
Codexis Laboratories India Private Limited, a corporation organized and existing under the laws of India and having a place of business at G-01, Prestige Loka, 7/1 Brunton Road, Bangalore – 560 025, India (“Codexis India”) and
Arch Pharmalabs Limited, a corporation organized and existing under the laws of India having a place of business at H wing,
4th Floor, Tex Centre, Chandivali, Mumbai, 400072, India
(“Arch”). 
 WHEREAS, Arch and Codexis India are parties to that certain Product Supply Agreement, effective as
of February 16, 2010 (the “PSA”) and the Memorandum of Understanding for Transfer Pricing related thereto (the “MOU”); and 
 WHEREAS, the parties desire to amend the MOU to modify Arch’s manufacturing costs as set forth herein. 
 NOW, THEREFORE, in consideration of the premises and mutual covenants contained in this Amendment, the parties agree as follows: 
 1. Definitions. The capitalized terms used in this Amendment shall have the meanings assigned to such terms in the MOU, unless otherwise defined herein. 

2. Amendment. Arch and Codexis India agree that the MOU shall be amended in the manner set forth below: 

 

	 	A.	The table and the language preceding such table that immediately follows Paragraph F in the definition of “Manufacturing Costs” in Exhibit A to the MOU shall
be replaced in its entirety with the following: 

 Notwithstanding anything to the contrary, combined Direct Labor
Expenses set forth in Paragraph B(ii), Indirect Expenses set forth in Paragraph C, and Overhead Expenses set forth in Paragraph D shall not, in respect of each Product, exceed the following amounts: 

 

			
	 Product
	  	 Current Overhead

[*]

	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 [*] Certain information in this document has been omitted and filed separately with the Securities
and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. 
 EXECUTION COPY

  

			
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]
	[*]	  	[*]

 The amounts set forth in the above table are subject to quarterly review by the Parties pursuant to
Section 3.1 of the MOU. 
 3. Ratification; Conflict. Except as otherwise expressly set forth in this Amendment, all
of the terms and conditions of the PSA and MOU shall remain in full force and effect. In the event of any conflict between the terms of this Amendment and the terms of the PSA and MOU, the terms of this Amendment shall control. 

4. Counterparts. This Amendment may be signed in one (1) or more counterparts, each of which will be deemed an original but
all of which together will constitute one and the same instrument. 
 IN WITNESS WHEREOF, a duly authorized representative of
each party has executed this Amendment as of the dates identified below, but the Amendment shall become effective on the Amendment Effective Date. 
  

									
	CODEXIS LABORATORIES INDIA PRIVATE LIMITED	 		 	ARCH PHARMALABS LIMITED
					
	By:	 	/s/    Douglas Sheehy	 		 	By:	 	/s/    Ajit Kamath
	Name:	 	Douglas Sheehy	 		 	Name:	 	Ajit Kamath
	Title:	 	Director	 		 	Title:	 	Chairman & Managing Director
	Date:	 	April 20,2011	 		 	Date:	 	April 25, 2011

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00195-of-00352.parquet"}]]